Neurocrine Biosciences (NBIX) has drawn fresh attention after announcing a Phase 1 first in human study of NBIP 1968, a triple agonist candidate aimed at obesity treatment and intended for once weekly subcutaneous dosing
The Phase 1 obesity study comes on the heels of Neurocrine Biosciences reporting higher second quarter and half year revenue and earnings for 2026, as well as a recent US$742m shelf registration related to an employee stock offering. The share price is at US$163.41, with a 90 day share price return of 4.88% and year to date share price return of 16.22%. The 1 year total shareholder return of 31.80% and 5 year total shareholder return of 81.20% point to momentum that has built over a longer period despite a softer 30 day share price return.
If this obesity update has you thinking about where else growth and AI meet in healthcare, it could be worth scanning 43 healthcare AI stocks as a starting list of ideas
Neurocrine Biosciences now sits at US$163.41 after a strong run and fresh attention on its obesity portfolio. Does that recent move already reflect the progress, or does the current valuation still leave room before waiting makes sense?
Advertisement
Most Popular Narrative: 23.3% Undervalued
The most followed Neurocrine Biosciences narrative points to a fair value of about $213 per share compared with the current $163.41, which implies investors are weighing strong commercial execution against pipeline and pricing questions
A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion. Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides) and a strong preclinical pipeline allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.
Curious what sits behind that higher fair value for Neurocrine Biosciences. The narrative leans heavily on compounding revenue, expanding margins, and a richer pipeline contribution. The valuation hinges on how far those trends can run and what multiple investors might accept on the other side
Result: Fair Value of $213.13 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts
However, for Neurocrine Biosciences, the story can change quickly if payer pushback on INGREZZA pricing worsens or key late stage CNS trials disappoint
Find out about the key risks to this Neurocrine Biosciences narrative
Next Steps
If the mix of pipeline potential and current pricing questions around Neurocrine Biosciences leaves you undecided, act while the data is fresh and test the thesis yourself. To see what rewards other investors are focusing on, review the 4 key rewards
Looking for more investment ideas beyond Neurocrine Biosciences?
Do not stop with a single stock. Broaden your watchlist using focused screeners that surface different types of opportunities before the next move gets fully priced in
- Spot potential value opportunities early by scanning 52 high quality undervalued stocks, which combine quality fundamentals with prices that may not fully reflect their financial profile.
- Strengthen your defensive side by reviewing 83 resilient stocks with low risk scores, which highlight companies with more resilient risk scores for steadier portfolio anchors.
- Hunt for underfollowed opportunities through the screener containing 21 high quality undiscovered gems, which pull together stocks with strong fundamentals but less crowded attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if Neurocrine Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:NBIX
Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally
See The Free Research Report
Flawless balance sheet and undervalued
See The Free Research Report
Similar Companies
NasdaqGS:AMGN
Amgen
NasdaqGS:INCY
Incyte
Market Insights
What Korea’s market says about your index fundMitchell Lawler
What does frontier-beating open source mean for AI investors?Andrew Legget
Why 2026’s worst-looking sector might be its most misreadMitchell Lawler
Advertisement
Weekly Picks
DA
davidlsanderon Optimi Health·6 days ago
OPTH: A licensed manufacturer already selling MDMA while peers still wait on trials
Fair Value:US$1257.9% undervalued
5followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
HA
HarishPKon Amdocs·about 2 months ago
Why Amdocs is a high conviction Buy for me?
Fair Value:US$82.0328.6% undervalued
36followersusers have followed this narrative
·3commentsusers have commented on this narrative
·12likesusers have liked this narrative
IV
Ivoedon SBM Offshore·about 1 month ago
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog
Fair Value:€44.524.7% undervalued
22followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
CL
Clive_Thompsonon Green Tea Group·13 days ago
One of China’s Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Fair Value:HK$8.719.3% undervalued
47followersusers have followed this narrative
·3commentsusers have commented on this narrative
·20likesusers have liked this narrative
RecentlyUpdated Narratives
AS
AstrisCorporateAdvisoryon Rigaku Holdings·about 3 hours ago
Capitalizing on rising semiconductor complexity
Fair Value:JP¥2.52k22.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
UM
UmarHashmion Lucky Cement·about 3 hours ago
Lucky Cement expected to bloom with 12% revenue growth
Fair Value:PK₨64029.0% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
RO
RockeTelleron Denarius Metals·about 4 hours ago
558% IRR Gold Project Already in Production, Colombia’s Next Major Producer
Fair Value:CA$110.1399.5% undervalued
26followersusers have followed this narrative
·3commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28020.0% undervalued
286followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price
Fair Value:US$419.9119.1% overvalued
149followersusers have followed this narrative
·0commentsusers have commented on this narrative
·8likesusers have liked this narrative
KI
KiwiInveston Amazon.com·3 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0942.2% undervalued
171followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
